

Matteo Fornai

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2783716/matteo-fornai-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

3,488
citations

35
h-index

51
g-index

141
ext. papers

4,166
ext. citations

6
avg, IF

5.22
L-index

#	Paper	IF	Citations
131	Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats. <i>Gastroenterology</i> , 2017 , 153, 1026-1039	13.3	108
130	Adenosine and inflammation: what's new on the horizon?. <i>Drug Discovery Today</i> , 2014 , 19, 1051-68	8.8	107
129	Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?. <i>Acta Neuropathologica</i> , 2018 , 136, 345-361	14.3	103
128	Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. <i>Current Drug Targets</i> , 2012 , 13, 842-62	3	96
127	Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 3656-3671	8.3	95
126	Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation. <i>Frontiers in Immunology</i> , 2017 , 8, 36	8.4	93
125	Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications 2008 , 120, 233-53		88
124	Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 322, 435-42	4.7	86
123	Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. <i>Hypertension</i> , 2013 , 62, 337-44	8.5	84
122	Adenosine signaling and the immune system: When a lot could be too much. <i>Immunology Letters</i> , 2019 , 205, 9-15	4.1	80
121	Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 312, 945-53	4.7	79
120	Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. <i>Clinical Therapeutics</i> , 2009 , 31 Pt 1, 1426-53	3.5	78
119	Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by alpha2-adrenoceptors in the presence of experimental colitis. <i>British Journal of Pharmacology</i> , 2003 , 139, 309-20	8.6	66
118	Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. <i>Hypertension</i> , 2007 , 49, 679-86	8.5	63
117	Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. <i>Hypertension</i> , 2009 , 53, 1008-16	8.5	56
116	Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. <i>World Journal of Gastroenterology</i> , 2005 , 11, 4052-60	5.6	55
115	Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 566-74	4.5	51

114	Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Journal of Neuroinflammation</i> , 2016 , 13, 146	10.1	50
113	Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. <i>Drug Discovery Today</i> , 2017 , 22, 1686-1696	8.8	50
112	Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. <i>Toxicology and Applied Pharmacology</i> , 2004 , 195, 62-72	4.6	49
111	Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug. <i>Clinical Drug Investigation</i> , 2002 , 22, 799-818	3.2	47
110	The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications. <i>Pharmacology & Therapeutics</i> , 2013 , 139, 157-88	13.9	45
109	NKG2A and COVID-19: another brick in the wall. <i>Cellular and Molecular Immunology</i> , 2020 , 17, 672-674	15.4	44
108	Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	43
107	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1407-14	3.6	43
106	Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. <i>Oncologist</i> , 2010 , 15, 1214-9	5.7	43
105	Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. <i>CNS Drugs</i> , 2014 , 28, 249-72	6.7	41
104	The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010 , 335, 434-42	4.7	41
103	Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. <i>Gut</i> , 2005 , 54, 608-16	19.2	41
102	Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?. <i>Progress in Neurobiology</i> , 2020 , 191, 101806	10.9	38
101	Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 1681-92	8.3	38
100	Enteric Dysfunctions in Experimental Parkinson's Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 356, 434-44	4.7	36
99	NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014 , 348, 86-95	4.7	36
98	Drug-induced taste and smell alterations: a case/non-case evaluation of an italian database of spontaneous adverse drug reaction reporting. <i>Drug Safety</i> , 2011 , 34, 849-59	5.1	36
97	Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005 , 372, 79-87	3.4	35

96	Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats. <i>PLoS ONE</i> , 2014 , 9, e116253	3.7	34
95	Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. <i>European Journal of Pharmacology</i> , 2011 , 650, 639-49	5.3	34
94	A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 117-22	4.5	34
93	Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome. <i>PLoS ONE</i> , 2013 , 8, e54831	3.7	34
92	The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. <i>PLoS ONE</i> , 2018 , 13, e0195502	3.7	33
91	Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1094	5.6	33
90	Inducible nitric oxide synthase is involved in endothelial dysfunction of mesenteric small arteries from hypothyroid rats. <i>Endocrinology</i> , 2009 , 150, 1033-42	4.8	32
89	Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. <i>Pharmacological Research</i> , 2009 , 59, 90-100	10.2	32
88	Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. <i>Neurogastroenterology and Motility</i> , 2016 , 28, 1781-1791	4	31
87	Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms. <i>Pharmacological Research</i> , 2011 , 63, 59-67	10.2	29
86	Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update. <i>Postgraduate Medicine</i> , 2010 , 122, 49-65	3.7	29
85	Differential role of cyclooxygenase 1 and 2 isoforms in the modulation of colonic neuromuscular function in experimental inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 317, 938-45	4.7	29
84	Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. <i>Translational Neurodegeneration</i> , 2019 , 8, 5	10.3	28
83	The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2016 , 20, 179-91	6.4	26
82	Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review. <i>Nutrition Research Reviews</i> , 2018 , 31, 239-247	7	26
81	Allopurinol adherence among patients with gout: an Italian general practice database study. <i>International Journal of Clinical Practice</i> , 2015 , 69, 757-65	2.9	26
80	Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. <i>European Heart Journal</i> , 2012 , 33, 2225-34	9.5	26
79	Control of enteric neuromuscular functions by purinergic A(3) receptors in normal rat distal colon and experimental bowel inflammation. <i>British Journal of Pharmacology</i> , 2010 , 161, 856-71	8.6	25

78	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A adenosine receptors. <i>Purinergic Signalling</i> , 2017 , 13, 497-510	3.8	24
77	Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. <i>British Journal of Pharmacology</i> , 2014 , 171, 1314-29	8.6	24
76	Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. <i>Pharmacology & Therapeutics</i> , 2010 , 125, 62-78	13.9	24
75	Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1340	5.6	24
74	A1 and A2a receptors mediate inhibitory effects of adenosine on the motor activity of human colon. <i>Neurogastroenterology and Motility</i> , 2009 , 21, 451-66	4	23
73	Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction. <i>Pharmacological Research</i> , 2005 , 52, 485-90	10.2	23
72	Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. <i>Pharmacological Research</i> , 2016 , 104, 186-96	10.2	22
71	Constitutive expression of cyclooxygenase-2 in the neuromuscular compartment of normal human colon. <i>Neurogastroenterology and Motility</i> , 2006 , 18, 654-62	4	22
70	A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1405	5.6	22
69	Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients. <i>Drugs and Aging</i> , 2008 , 25, 197-208	4.7	21
68	Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia. <i>FASEB Journal</i> , 2020 , 34, 5512-5524	0.9	20
67	An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. <i>Journal of Cellular and Molecular Medicine</i> , 2015 , 19, 485-500	5.6	20
66	Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment. <i>Digestive and Liver Disease</i> , 2009 , 41, 395-405	3.3	20
65	Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 284-291	6.1	19
64	Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. <i>Expert Review of Clinical Pharmacology</i> , 2015 , 8, 61-75	3.8	19
63	Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. <i>Drug Safety</i> , 2016 , 39, 903-24	5.1	18
62	Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. <i>International Journal of Obesity</i> , 2019 , 43, 331-343	5.5	18
61	Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1296-1305	3.8	16

60	Derivatives of benzimidazol-2-ylquinoline and benzimidazol-2-ylisoquinoline as selective A1 adenosine receptor antagonists with stimulant activity on human colon motility. <i>ChemMedChem</i> , 2011 , 6, 1909-18	3.7	15
59	P2X4 receptors, immunity, and sepsis. <i>Current Opinion in Pharmacology</i> , 2019 , 47, 65-74	5.1	14
58	High Levels of β -Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse. <i>Oxidative Medicine and Cellular Longevity</i> , 2019 , 2019, 5030475	6.7	14
57	Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. <i>British Journal of Pharmacology</i> , 2013 , 169, 554-66	8.6	14
56	Intestinal epithelial barrier and neuromuscular compartment in health and disease. <i>World Journal of Gastroenterology</i> , 2020 , 26, 1564-1579	5.6	14
55	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Neuropharmacology</i> , 2017 , 123, 22-33	5.5	13
54	Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. <i>Frontiers in Pharmacology</i> , 2018 , 9, 212	5.6	13
53	Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012 , 342, 140-9	4.7	13
52	Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2015 , 38, 869-88	5.1	12
51	Cholecystokinin CCK2 receptors mediate the peptide's inhibitory actions on the contractile activity of human distal colon via the nitric oxide pathway. <i>British Journal of Pharmacology</i> , 2007 , 151, 1246-53	8.6	12
50	Glial A Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity. <i>Cells</i> , 2020 , 9,	7.9	12
49	Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy. <i>Nutrition</i> , 2020 , 70, 110583	4.8	12
48	NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. <i>Medicinal Research Reviews</i> , 2021 , 41, 1890-1926	14.4	12
47	Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. <i>Neurobiology of Disease</i> , 2020 , 139, 104821	7.5	11
46	Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. <i>Vaccine</i> , 2011 , 29, 3443-8	4.1	11
45	Pathophysiology of Gastric Ulcer Development and Healing: Molecular Mechanisms and Novel Therapeutic Options 2011 ,		11
44	Telogen effluvium following bivalent human papillomavirus vaccine administration: a report of two cases. <i>Dermatology</i> , 2012 , 224, 212-4	4.4	11
43	Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship. <i>Cells</i> , 2020 , 9,	7.9	11

42	Anti-inflammatory effect of a novel locally acting A receptor agonist in a rat model of oxazolone-induced colitis. <i>Purinergic Signalling</i> , 2018 , 14, 27-36	3.8	11
41	Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
40	Neuronal regulation of intestinal immune functions in health and disease. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13406	4	10
39	Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. <i>Pharmacogenomics</i> , 2015 , 16, 523-39	2.6	9
38	Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. <i>British Journal of Pharmacology</i> , 2014 , 171, 3728-40	8.6	9
37	Effects of a bicarbonate-alkaline mineral water on digestive motility in experimental models of functional and inflammatory gastrointestinal disorders. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2008 , 30, 261-9		8
36	Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches. <i>Trends in Molecular Medicine</i> , 2020 , 26, 1021-1033	11.5	7
35	CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon. <i>European Journal of Pharmacology</i> , 2007 , 557, 212-20	5.3	7
34	Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
33	The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A Receptor Agonist, in a Rat Model of Colitis. <i>Cells</i> , 2020 , 9,	7.9	6
32	Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling. <i>Obesity</i> , 2020 , 28, 609-615	8	6
31	Cyclooxygenase-2 induction after oral surgery does not entirely account for analgesia after selective blockade of cyclooxygenase 2 in the preoperative period. <i>Anesthesiology</i> , 2006 , 104, 152-7	4.3	6
30	Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. <i>Expert Opinion on Drug Discovery</i> , 2020 , 15, 687-703	6.2	5
29	Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. <i>Minerva Gastroenterologica E Dietologica</i> , 2019 , 65, 298-308	1.6	5
28	The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
27	NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity. <i>British Journal of Pharmacology</i> , 2021 , 178, 3924-3942	8.6	5
26	Adenosine Regulation of the Immune System 2018 , 499-514		4
25	Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2013 , 21, 365-372	1.4	4

24	Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009 , 379, 305-13	3.4	4
23	Inflammatory Bowel Diseases: It's Time for the Adenosine System. <i>Frontiers in Immunology</i> , 2020 , 11, 1310	8.4	4
22	Risankizumab for the treatment of moderate to severe psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1-8	5.4	4
21	Adenosine Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1270, 145-167	3.6	4
20	Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy. <i>Pharmacological Reports</i> , 2020 , 72, 1347-1357	3.9	3
19	Tu1889 Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation. <i>Gastroenterology</i> , 2016 , 150, S968-S969	13.3	3
18	Transient acute liver failure complicating transurethral resection syndrome. <i>Scandinavian Journal of Urology and Nephrology</i> , 2010 , 44, 269-72		3
17	Tolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review. <i>Journal of Asthma</i> , 2007 , 44, 411-22	1.9	3
16	Enteric α -synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology.. <i>Npj Parkinson's Disease</i> , 2022 , 8, 9	9.7	3
15	Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?. <i>Frontiers in Pharmacology</i> , 2020 , 11, 621955	5.6	2
14	Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2021 , 12, 748021	5.6	2
13	Comment on "High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma". <i>Tumor Biology</i> , 2015 , 36, 7397-8	2.9	1
12	Response to Endothelial nitric oxide synthase, cyclooxygenase-2, and essential hypertension: is there an interaction?. <i>Hypertension</i> , 2013 , 62, e16	8.5	1
11	Improved tonsillar disposition of azithromycin following a 3-day oral treatment with 20 mg kg ⁻¹ in paediatric patients. <i>Pharmacological Research</i> , 2002 , 46, 95-100	10.2	1
10	Donepezil improves vascular function in a mouse model of Alzheimer's disease. <i>Pharmacology Research and Perspectives</i> , 2021 , 9, e00871	3.1	1
9	Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
8	The role of serotonin and its pathways in gastrointestinal disorders 2021 , 67-94		1
7	Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis.. <i>Inflammation</i> , 2022 , 1	5.1	1

6	P709 Early measurement of serum cytokines as predictor of clinical and endoscopic outcome to vedolizumab in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S475-S475	1.5
5	The flavonoid compound luteolin prevents endothelial dysfunction in a mouse model of high fat diet-induced obesity. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO4-2-47	0
4	FA-5, a novel AMP-activated protein kinase (AMPK) activator, as a new pharmacological tool for the management of bowel inflammation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO3-5-2	0
3	Rifaximin prevents diclofenac-induced enteropathy in rats through antibacterial and anti-inflammatory activities. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO3-5-28	0
2	A comparative study on the efficacy of NLRP3 inflammasome signaling inhibitors in a pre-clinical model of bowel inflammation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO2-6-29	0
1	P454 Serum oncostatin M predicts mucosal healing in Crohn's disease patients treated with infliximab. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S406-S406	1.5